GeneVentiv Therapeutics, founded with a mission to revolutionize the treatment of blood disorders, is a pre-clinical gene therapy company. Their core vision is to transform lives through innovative gene therapies. The company's flagship product, GENV-HEM, is the first universal gene therapy for hemophilias A and B, designed to work with or without inhibitors. Additionally, they are developing a gene therapy for Hemophilia Arthropathy, a degenerative joint disease. GeneVentiv primarily focuses on addressing unmet medical needs in the blood disorder market.

Notable affiliations include support from the National Hemophilia Foundation and an orphan drug designation from the FDA for GENV-HEM. The company has made significant strides in the gene therapy field, positioning itself as a pioneer in treating hemophilia through a single infusion, AAV-based approach. These achievements underscore GeneVentiv's potential impact on improving the quality of life for individuals with blood disorders, marking it as a key player in the biopharmaceutical industry.